Results 21 to 30 of about 62,619,193 (270)

Interleukin (IL)-12/23 and IL-23 Inhibitors

, 2023
Biologic therapies have transformed the treatment of moderate-to-severe psoriasis. This is a rapidly evolving field, with several new monoclonal antibody medications reaching the market over the last few years.
Warren, Richard B., Earnshaw, Charles, Warren, Richard B.; id_orcid   +2 more
core   +3 more sources

Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study [PDF]

Trials, 2021
Background Psoriasis is a chronic immune-mediated inflammatory skin disease for which biologics are effective treatments. Dose reduction (DR) of the first generation biologics seems a promising way for more efficient use of expensive biologics.
Lara S. van der Schoot, Juul M. P. A. van den Reek, Lynda Grine, Lisa Schots, Wietske Kievit, Jo L. W. Lambert, Elke M. G. J. de Jong   +6 more
doaj   +2 more sources

Off-label dermatologic uses of IL-23 inhibitors

Journal of Dermatological Treatment
Background While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have been associated with elevated IL-23 levels ...
Justin Porter, Lacey Zimmerman, Melissa Nickles, Sheryl Hoyer   +3 more
doaj   +3 more sources

Novel Pharmacological Approaches for Inflammatory Bowel Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 Axis [PDF]

International Journal of Inflammation, 2012
This review identifies possible pharmacological targets for inflammatory bowel disease (IBD) within the IL-23/IL-17 axis. Specifically, there are several targets within the IL-23/IL-17 pathways for potential pharmacological intervention with antibodies ...
Leo R. Fitzpatrick
doaj   +2 more sources

Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits [PDF]

Dermatology Practical & Conceptual
Introduction: Psoriasis is a chronic inflammatory multisystem disease for which IL-17 and IL-23 inhibitors have transformed treatment. However, high costs, and the possibility of overtreatment in patients with excellent and sustained responses have ...
Edoardo Cammarata, Chiara Airoldi, Jacopo Colombo, Andrealuna Ucciero, Luca Mastorino, Veronica Arese, Lorenza Burzi, Franco Castelli, Massimo Chiarpenello, Francesca Graziola, Claudia Leporati, Michela Ortoncelli, Pella Paolo, Ginevra Pertusi, Alessia Pisterna, Pietro Quaglino, Simone Ribero, Gianluca Rossotto, Rossana Tiberio, Paolo Dapavo, Paola Savoia   +20 more
doaj   +2 more sources

Efficacy and safety of IL-23 inhibitors in the treatment of moderate to severe ulcerative colitis: a meta-analysis based on randomized controlled trials [PDF]

Frontiers in Medicine
BackgroundInterleukin-23 (IL-23) plays a central role in the pathogenesis of ulcerative colitis (UC) by promoting Th17-mediated intestinal inflammation. While monoclonal antibodies targeting the IL-23p19 subunit have shown promise in clinical trials, the
Minyang He, Huixian Liang, Xiangcheng Fan, Xiangcheng Fan, Leimin Sun, Leimin Sun   +5 more
doaj   +2 more sources

Clinical case series: Emergence of psoriatic arthritis during biologic IL-23 pathway inhibition therapy for psoriasis [PDF]

Frontiers in Medicine
Psoriasis (PsO) and psoriatic arthritis (PsA) are increasingly recognized as manifestations within the spectrum of psoriatic disease, and emerging observational data suggest that biologic therapy targeting interleukin-23 (IL-23) may reduce the risk of ...
Andrew Z. Li, Ian D. Cooley, Ethan Craig, Chris T. Derk, Shubhasree Banerjee, Alexis R. Ogdie, Kelcie L. Molchany, Joel M. Gelfand   +7 more
doaj   +2 more sources

Efficacy of IL-23 inhibitors and IL-12/23 inhibitors in the induction treatment of Crohn’s disease: A meta-analysis based on randomized controlled trials [PDF]

Central European Journal of Immunology, 2023
Boyang Gao, Haojie Shentu, Suyong Sha, Dongying Wang, Xi Chen, Zhenwei Huang, Nan Dong, Haijia Lai, Jianying Xu, Xiaoshuai Zhou   +9 more
doaj   +2 more sources

Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis) [PDF]

Dermatology and Therapy
Introduction Psoriasis involving special or high-impact areas (scalp, nails, palms/soles, genitalia) is associated with a disproportionate functional and psychological burden that is often underestimated by conventional severity scores and remains ...
Emanuele Trovato, Alessandra Cartocci, Francesca Gaiani, Francesco Messina, Luca Mastorino, Nicole Macagno, Andrea Carugno, Marco Campoli, Maria Concetta Fargnoli, Viviana Lora, Agnese Rossi, Helena Gioacchini, Luca Potestio, Giovanni Marco D’Agostino, Martina Maurelli, Giampiero Girolomoni, Marco Romanelli, Valentina Dini, Francesco Loconsole, Francesca Satolli, Gianluca Pagnanelli, Claudia Lasagni, Andrea Michelerio, Martina Dragotto, Piergiorgio Malagoli, Nicola Zerbinati, Diego Orsini, Anna Campanati, Matteo Megna, Tommaso Bianchelli, for the Italian Landscape Group, Antonio Costanzo, Simone Ribero, Alessandra Narcisi   +33 more
doaj   +2 more sources

Comparative Role of Anti-TNF Agents versus IL-12/23 Inhibitors in Inflammatory Bowel Disease: An Updated Review [PDF]

The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
Treatments for Crohn's Disease (CD) and Ulcerative Colitis (UC), two conditions that fall under the umbrella of Inflammatory Bowel Disease (IBD), must be both safe and effective. This review compares the effectiveness and safety of anti-TNF agents and IL-
Xue Bin Leong, Chuan Zhe Tang, Chloe Zi Ying Lee, Zoe Ling Hui Lee, Thai Hau Koo   +4 more
doaj   +2 more sources